Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

NETWORK 3OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Dexamethasone 4nelarabine 3Calcium Dobesilate 2terameprocol 1ontuxizumab 1mogamulizumab 1isatuximab 1forodesine 1fludarabine phosphate 1fludarabine 1crenigacestat 1cobomarsen 1calaspargase pegol 1brincidofovir 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Sensitivity and Specificity 1Ranitidine 1Oxaliplatin 1Mycophenolic Acid 1Mesna 1Lenalidomide 1HBI-8000 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Fentanyl 1Diphenhydramine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × calaspargase pegol × Clear all
NCT04817761 2026-02-18

SPARK-ALL: Calaspargase Pegol in Adults With ALL

Servier

Phase 2/3 Terminated
42 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡